<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The term "gray-zone" <z:hpo ids='HP_0002665'>lymphoma</z:hpo> has been used to denote a group of <z:hpo ids='HP_0002665'>lymphomas</z:hpo> with overlapping histological, biological, and clinical features between various types of <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>It has been used in the context of Hodgkin <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (<z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>) and non-Hodgkin <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (NHL), including classical <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> (CHL), and primary mediastinal large B cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, cases with overlapping features between nodular lymphocyte predominant Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and T-cell/histiocyte-rich large B cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, CHL, and Epstein-Barr-virus-positive <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo>, and peripheral T cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> simulating CHL </plain></SENT>
<SENT sid="2" pm="."><plain>A second group of gray-zone <z:hpo ids='HP_0002665'>lymphomas</z:hpo> includes B cell NHL with intermediate features between diffuse large B cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and classical Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>In order to review controversial issues in gray-zone <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, a joint Workshop of the European Association for Hematopathology and the Society for Hematopathology was held in Bordeaux, France, in September 2008 </plain></SENT>
<SENT sid="4" pm="."><plain>The panel members reviewed and discussed 145 submitted cases and reached consensus diagnoses </plain></SENT>
<SENT sid="5" pm="."><plain>This Workshop summary is focused on the most controversial aspects of gray-zone <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and describes the panel's proposals regarding diagnostic criteria, terminology, and new prognostic and diagnostic parameters </plain></SENT>
</text></document>